Conference Speakers

David Stroncek the Director of the Center for Cellular Engineering (CCE) and acting Chief, Department of Transfusion Medicine at the NIH Clinical Center. The CCE is a comprehensive facility that develops and manufactures a wide range of cell and gene therapies for phase 1 and 2 clinical trials. The CCE is currently manufacturing CAR T-cells, TCR-engineered T-cells, cancer vaccines, induced pluripotent stem cells (iPSC), retinal pigmented epithelial cells derived from autologous iPSC and genetically modified hematopoietic stems cells. In past the CCE has manufactured dendritic cells, NK cells, virus specific T-cells and mesenchymal stromal cells. The CCE also processes hematopoietic stem cells for transplantation.

He received a bachelor’s of science degree in Chemical Engineering and a Medical Degree from the University of Minnesota. He completed residence training in internal medicine and fellowship training in hematology and oncology at the University of Minnesota.

David Stroncek’s research is focused on investigating new measures of cell and gene therapy quality and potency and developing new manufacturing methods to improve the consistency and quality of cell and gene therapies cells.